Literature DB >> 27092342

The year's new drugs & biologics 2015 - part II:Trends and highlights that marked a complicated year.

A I Graul1, E Cruces2, C Dulsat2, M Tracy2.   

Abstract

This eagle's-eye overview of the drug industry in 2015 provides insight into some of last year's top stories, including drug pricing, orphan drug development, the FDA's priority review voucher system, pipeline attrition, and the ongoing movement in M&A. We also take a look into the crystal ball and anticipate the new drugs that may reach the market in 2016. Copyright 2016 Prous Science, S.A.U. or its licensors. All rights reserved.

Entities:  

Keywords:  Discontinuations; Drug pricing; FDA; Orphan drug; Priority review; Voucher

Mesh:

Substances:

Year:  2016        PMID: 27092342     DOI: 10.1358/dot.2016.52.2.2472346

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  1 in total

1.  Phase II and phase III failures: 2013-2015.

Authors:  Richard K Harrison
Journal:  Nat Rev Drug Discov       Date:  2016-11-04       Impact factor: 84.694

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.